Most researchers seeking out CJC-1295 in Myrne quickly find that local retail options are all but absent from local stores. The upside of this online-only market is that serious vendors are judged entirely by their analytical documentation, giving researchers better verification tools than any physical store could provide. What genuinely separates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. Use this guide to verify vendor quality systematically — the standards covered in this guide are universal across all research contexts.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Myrne researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Before looking at individual vendors, establish a quality benchmark — so you can recognise whether a vendor meets it. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are at acceptable levels for the intended application. Strong quality indicators beyond COA quality: established track record of at least two years, knowledgeable support capable of explaining COA data, and shipping with desiccant and appropriate cold protection. Store lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and store the rest at −20°C.
Order CJC-1295 — ships to Myrne
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and small-scale human observations. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg in 2mL gives a 2.5mg/mL solution — or 25mcg per insulin syringe unit. Verify the endotoxin level in your CJC-1295 batch COA before use in any in-vivo protocol — look for results expressed as EU/mg or EU/mL and verify they are within the acceptable range for your research context. PubMed and related preprint servers are the primary literature resources for CJC-1295 research; focus on peer-reviewed publications with documented compound quality over case reports or anecdotal evidence.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
